Open Nav

Trimeric Therapeutics, Inc.

  • John Commissiong, Trimeric Therapeutics, Inc.

To present Trimeric to the Bitech World; Raise capital

  • Date:Thursday, October 18
  • Time:9:45 AM - 10:00 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Our lead drug candidate, MANF, was designed to treat Parkinson’s disease (PD), and later shown to be effective in retinal diseases as well. MANF is a neurotrophic factor (NTF), and an endoplasmic reticulum (ER) stress response (SR) protein, localized in the ER/Golgi complex. It is also secreted. The USPTO and EPO have awarded MANF orphan drug designation (ODD) for retinitis pigmentosa (RP). MANF is effective in animal models of PD, and in rodent models of RP and glaucoma.There are10-M PD patients worldwide, with 1.0-M in the US. Reimbursement will likely average $100,000 initially in the US and Europe. All MANF-related IP will be transferred from Amarantus Bioscience to Trimeric Therapeutics. We are seeking seed capital of $3.0-M to implement specific milestones, with an IND for PD, projected for Q4/2019. Projects: Manufacture of cGMP MANF protein (Catalent); toxicology; PK/PD; Hire CDO and VP Reg Affairs. Sr Man: Saad Naseer, MD, MBA: CEO & CMO: John Commissiong, PhD: Pres & CSO:
  • Company Website:(Under construction)
  • Company HQ City:San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:John Commissiong/President
  • Year Founded:2018
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :MANF: Mesencephalic Astrocyte-derived Neurotrophic Factor
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Additional Information/Comments:The MANF technology in the public company Amarantus Bioscience Holdings, has been extracted entirely into a new private company, Trimeric Therapeutics, Inc. with its own Senior Management Team, Board of Directors, Scientific Advisory Board and Senior Advisers. Our aim is to expedite the development of MANF into the clinic by focusing entirely on this Product. Amarantus will continue to develop eltoprazine, ESS and other assets. MANF was designed to treat PD. The biology, unique molecular structure, evolutionary history and endoplasmic reticulum (ER)/unfolded protein response (UPR) properties, and its ability to promote the growth of dopaminergic terminals in the putamen all point to a PD drug candidate that is entirely different from previous ones. Our objective is to maintain patients symptom-free for 15 years after diagnosis, without the use of L-DOPA. The origin of MANF from a protoplasmic astrocyte cell line is in keeping with the new understanding of astrocyte/neuron biology.
  • Previous and Current Investors:None yet. In discussion with several top tier investors.
  • Size of Last Investment Round:$0
  • Total Amount Raised to Date, In All Rounds:$0
John Commissiong
Trimeric Therapeutics, Inc.